Cellectis S.A. (CLLS)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Cellectis S.A. (CLLS) is down 36.2% since the beginning of the year. At $3 per share, CLLS is trading 43.6% below its 52-week high of $5. Investors who bought $1,000 worth of CLLS shares 5 years ago would now be looking at an investment worth $212.

Cellectis S.A. (CLLS) has returned -36.16% so far this year and 111.64% over the past 12 months. Over the last ten years, CLLS has returned -21.00% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.

Based on dividend-adjusted daily data since Mar 25, 2015, CLLS's average daily return is +0.03%, while the average monthly return is +0.44%. At this rate, an investment would double in approximately 13.2 years.

Historically, 45% of months were positive and 55% were negative. The best month was Nov 2023 with a return of +207.2%, while the worst month was Mar 2020 at -41.1%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 6 months.

On a daily basis, CLLS closed higher 47% of trading days. The best single day was Nov 1, 2023 with a return of +172.2%, while the worst single day was Oct 8, 2021 at -24.2%.

Cellectis S.A. has an annualized alpha of -9.92%, beta of 1.39, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since March 26, 2015.

• This stock participated in 220.68% of S&P 500 Index downside but only 123.74% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CLLS ranks 78 for risk / return — better than 78% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Cellectis S.A. (CLLS) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Cellectis S.A.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Cellectis S.A. was 97.96%, occurring on Oct 31, 2023. The portfolio has not yet recovered.

The current Cellectis S.A. drawdown is 93.52%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Cellectis S.A. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Cellectis S.A. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.